Sionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 21 2025
0mins
Source: Globenewswire
Sionna Therapeutics Presentation: Sionna Therapeutics will present preclinical data on its CFTR modulators and NBD1 stabilizers at the European Cystic Fibrosis Society Conference from June 4-7, 2025, in Milan, Italy.
Company Mission: The company aims to improve cystic fibrosis treatment by developing medicines that stabilize the CFTR protein, particularly targeting the F508del genetic mutation to enhance clinical outcomes and quality of life for patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
